查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1609604

抗體契約製造市場規模、佔有率、趨勢分析報告：按產品、原產地、最終用途、地區、細分市場預測，2025-2030

Antibodies Contract Manufacturing Market Size, Share & Trends Analysis Report, By Product (Monoclonal Antibodies, Polyclonal Antibodies, Others), By Source, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

抗體契約製造市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球抗體契約製造市場規模預計將達到317.6億美元，2025年至2030年複合年成長率為10.1%。

治療性抗體生產的需求不斷增加是預測期內推動市場成長的主要因素。抗體是精確針對異常細胞的關鍵生物製藥。於是，許多生物製藥公司開始專注於開發先進的抗體來治療癌症、關節炎、風濕性心臟疾病等慢性疾病。由於單株抗體療法用於治療 COVID-19 患者，COVID-19 的影響正在推動市場成長。

主要企業抗體製造研發預算的快速增加也推動了市場成長。在持續對抗 COVID-19 的鬥爭中，單株抗體 (mAb) 療法已被證明是一種有效的治療方法。這種治療的目標是防止住院、減少病毒量並最大程度地減輕症狀的嚴重程度。

在冠狀病毒大流行期間，生物製藥公司的供應鏈仍然強勁，並且在全球範圍內基本上沒有受到影響。同樣，抗體契約製造製造商也發現，用於生產與 COVID-19 疫苗和療法相關的抗體的需求不斷增加。由此可見，未來抗體契約製造市場蘊藏著許多商機。例如，2021 年 12 月，三星生物製品公司與阿斯特捷利康簽署了一項協議，生產 Evusheld，這是一種二元抗體組合，正在開發用於潛在治療 COVID-19。

CMO 的成長高度依賴生物製藥產業提供的機會。生命科學領域創業投資的擴張和整合是預計推動市場發展的兩個關鍵機會。例如，2022 年，FUJIFILM Diosynth Biotechnologies 宣佈在北卡羅來納州擴張。透過此次擴張，該公司計劃在 2024 年增加其技術職位，包括研究人員和科學家，並創建強大的商業流程。

抗體契約製造市場報告亮點

  • 由於哺乳動物表現系統在生技藥品開發中的高滲透率，基於單株抗體的抗體契約製造在 2024 年佔據了最大的市場佔有率，約為 76.42%。
  • 根據該市場提供的資料，哺乳動物細分市場在 2024 年將佔據最大佔有率，達到 57.52%，因為它被認為更可靠、穩健且相對成熟的技術。
  • 隨著印度、韓國和中國等新興經濟體擁抱發展以保持競爭力，預計亞太地區將成為預測期內成長最快的區域市場。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 抗體契約製造市場的變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 產業挑戰
  • 市場分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 分析

第4章 抗體契約製造市場：產品預估及趨勢分析

  • 細分儀表板
  • 產品變異分析
  • 按產品分類，2018-2030
  • 單株抗體
  • 多株抗體
  • 其他

第5章 起源商業分析

  • 細分儀表板
  • 起源變異分析
  • 按來源地分類，2018-2030
  • 哺乳動物起源
  • 微生物

第 6 章最終用途業務分析

  • 細分儀表板
  • 最終用途變化分析
  • 按最終用途分類，2018-2030
  • 生物製藥公司
  • 研究實驗室
  • 其他

第7章 抗體契約製造市場：區域估算與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 科威特

第8章 競爭格局

  • 參與企業
  • 策略規劃
  • 2024 年企業市場分析（企業熱圖分析）
  • 公司簡介
    • Lonza
    • Samsung Biologics
    • WuXi Biologics
    • Charles River Laboratories
    • FUJIFILM Holdings Corporation
    • Boehringer Ingelheim GmbH
    • AGC Biologics
    • Cytovance Biologics, Inc.
    • EMERGENT
    • Thermo Fisher Scientific, Inc.
    • Catalent, Inc
    • Laboratory Corporation of America Holdings
Product Code: GVR-4-68039-920-3

Antibodies Contract Manufacturing Market Growth & Trends:

The global antibody contract manufacturing market size is expected to reach USD 31.76 billion by 2030, registering a CAGR of 10.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rise in demand for the production of therapeutic antibodies is the main factor that will drive the growth of the market during the forecast period. Antibodies are the leading biopharmaceutical products that precisely target abnormal cells. Thus, many biopharmaceutical companies have begun to focus on the development of advanced antibodies for the treatment of chronic diseases such as cancer, arthritis, and rheumatic heart disease. The impact of COVID-19 has boosted the market growth, with the application of monoclonal antibodies therapy used as a treatment for COVID-19 patients.

A surge in the R&D budget for the production of antibodies by key players is also driving the growth of the market. For the ongoing fight against COVID-19, Monoclonal antibody (mAb) therapy is proven to be an effective treatment. The aim of this treatment is to prevent hospitalizations, decrease viral loads, and minimize symptom severity.

During the coronavirus outburst, the supply chain of biopharmaceutical companies remained robust and was largely unaffected worldwide. Similarly, antibody contract manufacturers are observing a rise in demand for the production of antibodies that will be used for treatments related to the COVID-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the antibody contract manufacturing market. For instance, in December 2021, an agreement was formed between Samsung Biologics and AstraZeneca to manufacture Evusheld, which is an amalgamation of binary antibodies in development for the potential treatment of COVID-19.

The growth of CMOs is greatly dependent on favorable opportunities offered by the biopharmaceutical industry. Expansion and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market. For instance, in 2022, FUJIFILM Diosynth Biotechnologies announced an expansion in North Carolina; with this expansion, the company will increase skilled positions including researchers and scientists by 2024 to generate strong commercial processes

Antibodies Contract Manufacturing Market Report Highlights:

  • Monoclonal antibodies-based antibody contract manufacturing captured the largest market share about 76.42% in 2024, owing to the high penetration of mammalian expression systems for biologics development
  • Based on the source offered in this market, the mammalian segment contributed the largest share of 57.52% in 2024, as they are considered a more reliable, robust, and relatively mature technology
  • Asia Pacific is expected to emerge as the fastest-growing regional market during forecast period, owing to developing economies such as India, South Korea, and China incorporating developments to sustain the competition

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
      • 1.7.1.1. Approach 1: Commodity flow approach
    • 1.7.2. Volume price analysis (Model 2)
      • 1.7.2.1. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Antibody Contract Manufacturing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
    • 3.2.2. Market Restraints Analysis
    • 3.2.3. Industry Challenges
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Analysis

Chapter 4. Antibody Contract Manufacturing Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Product Movement Analysis
  • 4.3. Antibody Contract Manufacturing Market Estimates & Forecasts, by Product, 2018 - 2030 (USD Million)
  • 4.4. Monoclonal Antibodies
    • 4.4.1. Monoclonal Antibodies Market Estimates & Forecasts, by Source, 2018 - 2030 (USD Million)
  • 4.5. Polyclonal Antibodies
    • 4.5.1. Polyclonal Antibodies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Source Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. Source Movement Analysis
  • 5.3. Antibody Contract Manufacturing Market Estimates & Forecasts, by Source, 2018 - 2030 (USD Million)
  • 5.4. Mammalian Source
    • 5.4.1. Mammalian Source Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Microbial
    • 5.5.1. Microbial Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. End Use Business Analysis

  • 6.1. Segment Dashboard
  • 6.2. End Use Movement Analysis
  • 6.3. Antibody Contract Manufacturing Market Estimates & Forecasts, by End Use, 2018 - 2030 (USD Million)
  • 6.4. Biopharmaceutical Companies
    • 6.4.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Research Laboratories
    • 6.5.1. Research Laboratories Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Antibody Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 7.1. Regional market share analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. North America
    • 7.3.1. U.S. Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Landscape
      • 7.3.2.4. U.S. Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Landscape
      • 7.3.3.4. Canada Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Landscape
      • 7.3.4.4. Mexico Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Landscape
      • 7.4.2.4. UK Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Landscape
      • 7.4.3.4. Germany Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Landscape
      • 7.4.4.4. France Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Landscape
      • 7.4.5.4. Italy Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Landscape
      • 7.4.6.4. Spain Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Landscape
      • 7.4.7.4. Denmark Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Competitive Scenario
      • 7.4.8.3. Regulatory Landscape
      • 7.4.8.4. Sweden Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Competitive Scenario
      • 7.4.9.3. Regulatory Landscape
      • 7.4.9.4. Norway Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Landscape
      • 7.5.2.4. China Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Japan
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Landscape
      • 7.5.3.4. Japan Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Landscape
      • 7.5.4.4. India Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Landscape
      • 7.5.5.4. South Korea Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Australia
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Landscape
      • 7.5.6.4. Australia Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Landscape
      • 7.5.7.4. Thailand Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Landscape
      • 7.6.2.4. Brazil Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Landscape
      • 7.6.3.4. Argentina Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Middle East and Africa
    • 7.7.1. Middle East and Africa Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Landscape
      • 7.7.2.4. Saudi Arabia Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Landscape
      • 7.7.3.4. UAE Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.4. South Africa
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Landscape
      • 7.7.4.4. South Africa Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Landscape
      • 7.7.5.4. Kuwait Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2024 (Company Heat Map Analysis)
  • 8.4. Company Profiles
    • 8.4.1. Lonza
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Service Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Samsung Biologics
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Service Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. WuXi Biologics
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Service Benchmarking
    • 8.4.4. Charles River Laboratories
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Service Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. FUJIFILM Holdings Corporation
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Service Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Boehringer Ingelheim GmbH
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Service Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. AGC Biologics
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Service Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Cytovance Biologics, Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Service Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. EMERGENT
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Service Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Thermo Fisher Scientific, Inc.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Service Benchmarking
      • 8.4.10.4. Strategic Initiatives
      • 8.4.10.5. Strategic Initiatives
    • 8.4.11. Catalent, Inc
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Service Benchmarking
      • 8.4.11.4. Strategic Initiatives
    • 8.4.12. Laboratory Corporation of America Holdings
      • 8.4.12.1. Participant's Overview
      • 8.4.12.2. Financial Performance
      • 8.4.12.3. Service Benchmarking
      • 8.4.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 4 Global Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 5 Global Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 6 Global Antibody Contract Manufacturing, by Region, 2018 - 2030 (USD Million)
  • Table 7 U.S. Antibody Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 8 U.S. Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 9 U.S. Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 10 U.S. Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 11 U.S. Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 12 U.S. Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 13 U.S. Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 14 U.S. Canada Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 15 Canada Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 16 Canada Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 17 Mexico Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 18 Mexico Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 19 Mexico Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 20 Europe Antibody Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 22 Europe Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 23 Europe Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 24 Germany Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 25 Germany Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 26 Germany Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 27 UK Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 28 UK Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 29 UK Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 30 France Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 31 France Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 32 France Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 33 Italy Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 34 Italy Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 35 Italy Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 36 Spain Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 37 Spain Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 38 Spain Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 39 Denmark Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 40 Denmark Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 41 Denmark Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 42 Sweden Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 43 Sweden Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 44 Sweden Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 45 Norway Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 46 Norway Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 47 Norway Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Antibody Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 52 China Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 53 China Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 54 China Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 55 Japan Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 56 Japan Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 57 Japan Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 58 India Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 59 India Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 60 India Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 61 South Korea Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 62 South Korea Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 63 South Korea Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 64 Australia Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 65 Australia Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 66 Australia Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 67 Thailand Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 68 Thailand Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 69 Thailand Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 70 Latin America Antibody Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 71 Latin America Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 72 Latin America Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 73 Latin America Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 74 Latin America Antibody Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 75 Brazil Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 76 Brazil Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 77 Brazil Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 78 Argentina Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 79 Argentina Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 80 Argentina Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Antibody Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 85 South Africa Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 86 South Africa Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 87 South Africa Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 91 UAE Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 92 UAE Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 93 UAE Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 94 UAE Antibody Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 97 Kuwait Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Antibody Contract Manufacturing, Market Segmentation
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Market Dynamics
  • Fig. 8 Market Driver Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Porter's Five Forces Analysis
  • Fig. 11 PESTEL Analysis, By SWOT Analysis
  • Fig. 12 Regional Marketplace: Key Takeaways
  • Fig. 13 Global Antibody Contract Manufacturing, for Monoclonal Antibodies, 2018 - 2030 (USD Million)
  • Fig. 14 Global Antibody Contract Manufacturing, for Polyclonal Antibodies, 2018 - 2030 (USD Million)
  • Fig. 15 Global Antibody Contract Manufacturing, for Others, 2018 - 2030 (USD Million)
  • Fig. 16 Global Antibody Contract Manufacturing, for Mammalian, 2018 - 2030 (USD Million)
  • Fig. 17 Global Antibody Contract Manufacturing, for Microbial, 2018 - 2030 (USD Million)
  • Fig. 18 Global Antibody Contract Manufacturing, for Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 19 Global Antibody Contract Manufacturing, for Research Laboratories, 2018 - 2030 (USD Million)
  • Fig. 20 Global Antibody Contract Manufacturing, for others, 2018 - 2030 (USD Million)
  • Fig. 21 Regional Outlook, 2024 & 2030
  • Fig. 22 U.S. Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Canada Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Mexico Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Europe Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 UK Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Germany Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 France Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Italy Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Spain Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Denmark Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Sweden Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Norway Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Asia Pacific Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 India Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 China Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Japan Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 South Korea Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Australia Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Thailand Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Latin America Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Brazil Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Argentina Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Colombia Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Middle East & Africa Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 South Africa Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Saudi Arabia Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 UAE Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Kuwait Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)